vs
Side-by-side financial comparison of ACME UNITED CORP (ACU) and Organogenesis Holdings Inc. (ORGO). Click either name above to swap in a different company.
ACME UNITED CORP is the larger business by last-quarter revenue ($52.3M vs $37.2M, roughly 1.4× Organogenesis Holdings Inc.). On growth, ACME UNITED CORP posted the faster year-over-year revenue change (13.8% vs -57.1%). Over the past eight quarters, ACME UNITED CORP's revenue compounded faster (-2.9% CAGR vs -46.5%).
Acme United Corporation is a supplier of cutting, measuring and safety products for the school, home, office, hardware and industrial markets. The company was organized as a partnership in 1867 and incorporated in 1873 under the laws of the State of Connecticut. It is publicly traded on the NYSE American with symbol ACU.
Organogenesis Holdings Inc. is a leading regenerative medicine firm specializing in developing and manufacturing advanced therapeutic products for wound care, surgical repair, sports medicine, and dermatology. It serves healthcare providers and patients primarily in the U.S. and select international markets, offering clinically validated solutions for unmet medical needs.
ACU vs ORGO — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $52.3M | $37.2M |
| Net Profit | $985.0K | — |
| Gross Margin | 39.7% | 30.8% |
| Operating Margin | 3.3% | -185.1% |
| Net Margin | 1.9% | — |
| Revenue YoY | 13.8% | -57.1% |
| Net Profit YoY | -40.4% | — |
| EPS (diluted) | $0.24 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $52.3M | $37.2M | ||
| Q4 25 | $47.5M | $225.6M | ||
| Q3 25 | $49.1M | $150.9M | ||
| Q2 25 | $54.0M | $101.0M | ||
| Q1 25 | $46.0M | $86.7M | ||
| Q4 24 | $45.9M | $126.7M | ||
| Q3 24 | $48.2M | $115.2M | ||
| Q2 24 | $55.4M | $130.2M |
| Q1 26 | $985.0K | — | ||
| Q4 25 | $1.9M | $43.7M | ||
| Q3 25 | $1.9M | $21.6M | ||
| Q2 25 | $4.8M | $-9.4M | ||
| Q1 25 | $1.7M | $-18.8M | ||
| Q4 24 | $1.7M | $7.7M | ||
| Q3 24 | $2.2M | $12.3M | ||
| Q2 24 | $4.5M | $-17.0M |
| Q1 26 | 39.7% | 30.8% | ||
| Q4 25 | 38.2% | — | ||
| Q3 25 | 39.1% | — | ||
| Q2 25 | 41.0% | — | ||
| Q1 25 | 39.0% | 72.6% | ||
| Q4 24 | 38.7% | 75.5% | ||
| Q3 24 | 38.5% | 76.7% | ||
| Q2 24 | 40.8% | 77.6% |
| Q1 26 | 3.3% | -185.1% | ||
| Q4 25 | 6.1% | 28.1% | ||
| Q3 25 | 6.1% | 13.7% | ||
| Q2 25 | 11.8% | -12.5% | ||
| Q1 25 | 5.3% | -30.9% | ||
| Q4 24 | 5.0% | 8.1% | ||
| Q3 24 | 6.1% | 5.4% | ||
| Q2 24 | 11.5% | -10.7% |
| Q1 26 | 1.9% | — | ||
| Q4 25 | 3.9% | 19.4% | ||
| Q3 25 | 3.9% | 14.3% | ||
| Q2 25 | 8.8% | -9.3% | ||
| Q1 25 | 3.6% | -21.7% | ||
| Q4 24 | 3.7% | 6.1% | ||
| Q3 24 | 4.6% | 10.7% | ||
| Q2 24 | 8.0% | -13.1% |
| Q1 26 | $0.24 | — | ||
| Q4 25 | $0.46 | $0.31 | ||
| Q3 25 | $0.46 | $0.11 | ||
| Q2 25 | $1.16 | $-0.10 | ||
| Q1 25 | $0.41 | $-0.17 | ||
| Q4 24 | $0.43 | $0.05 | ||
| Q3 24 | $0.54 | $0.09 | ||
| Q2 24 | $1.09 | $-0.13 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $4.2M | $91.4M |
| Total DebtLower is stronger | $33.0M | — |
| Stockholders' EquityBook value | $116.7M | — |
| Total Assets | $195.2M | $520.0M |
| Debt / EquityLower = less leverage | 0.28× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $4.2M | $91.4M | ||
| Q4 25 | $3.6M | $93.7M | ||
| Q3 25 | $5.1M | $63.7M | ||
| Q2 25 | $3.6M | $73.1M | ||
| Q1 25 | $3.4M | $110.0M | ||
| Q4 24 | $6.4M | $135.6M | ||
| Q3 24 | $5.7M | $94.3M | ||
| Q2 24 | $3.8M | $89.9M |
| Q1 26 | $33.0M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $62.3M | ||
| Q2 24 | — | $63.8M |
| Q1 26 | $116.7M | — | ||
| Q4 25 | $117.6M | $300.1M | ||
| Q3 25 | $115.8M | $255.1M | ||
| Q2 25 | $113.7M | $233.2M | ||
| Q1 25 | $108.3M | $242.9M | ||
| Q4 24 | $107.0M | $262.9M | ||
| Q3 24 | $106.3M | $278.5M | ||
| Q2 24 | $104.0M | $263.5M |
| Q1 26 | $195.2M | $520.0M | ||
| Q4 25 | $171.0M | $598.7M | ||
| Q3 25 | $173.0M | $509.8M | ||
| Q2 25 | $170.9M | $461.1M | ||
| Q1 25 | $163.0M | $467.4M | ||
| Q4 24 | $162.2M | $497.9M | ||
| Q3 24 | $165.5M | $446.3M | ||
| Q2 24 | $173.5M | $443.2M |
| Q1 26 | 0.28× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.22× | ||
| Q2 24 | — | 0.24× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
